News & events Type your keyword Filter - Any -ArticleEventNews 10 January 2022 Study uncovers how cancers resist targeted treatment Scientists have revealed how cancer can resist PARP inhibitors, a precision medicine used to treat thousands of patients worldwide. 06 January 2022 First clinical trial of innovative drug targeting HSF1 pathway begins The first cancer patients are to receive doses of an innovative new drug that targets a master regulatory pathway in cells, as part of a new clinical trial. The drug, called NXP800, was discovered at The Institute of Cancer Research, London, and targets the pathway regulated by the HSF1 transcription factor. 13 December 2021 Trial identifies five-drug combo for ‘ultra high risk’ bone marrow cancer A combination of five existing drugs keeps cancer at bay for longer in patients with a highly aggressive type of bone marrow cancer, a major new trial reveals. 09 December 2021 ICR calls for urgent investment to help recover cancer clinical trials The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying the development of cutting-edge drugs and technologies. 01 December 2021 BRC Research Advent Calendar In December, the NIHR Biomedical Research Centre (BRC) at The Royal Marsden and ICR is running a research-focused advent calendar campaign on Twitter to celebrate research news and successes from the past year. 19 November 2021 ICR and The Royal Marsden researchers named among world's most influential scientists Six researchers at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, have been named in a list of the world's most influential and innovative researchers over the last decade. 05 November 2021 Scientists identify potential new drug combination for children with incurable brain cancer Combining two existing cancer drugs could offer promise for some children with an incurable childhood brain cancer, a new study suggests. 04 November 2021 Royal Marsden partnership to create state-of-the-art in-house liquid biopsy testing facility The Royal Marsden NHS Foundation Trust will establish a state-of-the-art liquid biopsy testing facility for cancer clinical diagnostics and research following a partnership with Guardant Health, a leading precision oncology company. 03 November 2021 Consultant at The Royal Marsden appointed as the NIHR's national cancer lead for screening, prevention and early detection Dr Richard Lee, Consultant Respiratory Physician and Champion for Early Cancer Diagnosis at The Royal Marsden NHS Foundation Trust, has been appointed as the NIHR's national cancer lead for screening, prevention and early detection. Dr Lee will combine his lead NIHR role for screening, prevention and early detection of cancer and non-cancerous conditions with his existing responsibilities. 28 October 2021 Clinical trial provides new immunotherapy insights for kidney cancer Researchers at The Royal Marsden, Francis Crick Institute and University College London (UCL) have found immune cell patterns within tumours that can help predict whether patients with kidney cancer will respond to immunotherapy. Results from the ADAPTeR clinical trial were published in Cancer Cell journal on Thursday 28 October. ‹ Previous 1 2 3 4 5 6 7 8 9 Next ›